Skip to content

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2011-005239-14-FI
Enrollment
40
Registered
2012-01-05
Start date
2012-01-05
Completion date
Unknown
Last updated
2016-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MedDRA version: 14.1 Level: LLT Classification code 10010495 Term: Congenital heart disease NOS System Organ Class: 10010331 - Congenital, familial and genetic disorders

Interventions

Trade Name: Solu-Medrol 40 mg/ml Pharmaceutical Form: Concentrate and solvent for injection Pharmaceutical form of the placebo: Infusion Route of administration of the placebo: Intravenous use Trade

Sponsors

Pertti Suominen
Lead Sponsor
Pertti Suominen
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? yes Number of subjects for this age range: F.1.2 Adults (18-64 years) no F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):

Countries

Finland

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026